A Short Acting Beta-Agonist Reduction Program and Its Effects on Asthma Care in a Large Cohort

An asthma medication ratio (AMR) ≥0.5 is associated with decreased healthcare utilization improving patient-centered outcomes in persistent asthma. There is limited literature on outcomes after restricting short acting beta-agonist (SABA) refills. We hypothesized that a multidisciplinary SABA-Reduction Program (SABA-RP), which included limitations on refills, would significantly increase the percentage of patients fulfilling an AMR of ≥0.5, the number of asthma controller medications (CM) divided by the total of asthma medications (CM plus SABA).

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EBRhzq